drug
efzofitimod
Phase 2updated 3mo agoby $ATYR aTYR PHARMA INC
Phase 2community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying efzofitimod
- phase3Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
- phase2Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- phase2Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
- phase2Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis
News(1)
- aTyr lays off 60% of workforce to fund 2nd attempt at phase 3 success for lung disease drugSixty per cent of aTyr Pharma’s workforce are heading for the exits as the biotech conserves resources for a second shot at phase 3 success in a type of lung disease.fiercebiotech · 7d ago
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that